IMT Tours

The team of Molecular and Therapeutic Innovation bases its research of the conception of small heterocyclic chemical inhibiters, or activators for antitumor application, on protein bioconjugation, principally therapeutic monoclonal antibodies. Their skills range from the development of new methods of organic synthesis to the optimization of bioactive molecules in medicinal chemistry. Analytical expertise has also enabled the development of a platform for physicochemical analysis and measurement of aggregates in the formulation of biomedicines.